References
- Xia M Q, Tone M, Packman L, Hale G, Waldmann H. Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol 1991; 21: 1677–1684
- Hale G, Hoang T, Prospero T, Watt S M, Waldmann H. Removal of T cells from bone marrow for transplantation. Comparison of rat monoclonal anti-lymphocyte antibodies of different isotypes. Mol Biol Med 1983; 1: 305–319
- Wing M G, Moreau T, Greenwood J, Smith R M, Hale G, Isaacs J, et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 1996; 98: 19–26
- Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer M J, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998; 22: 185–191
- Domagala A, Kurpisz M. CD52 antigen—a review. Med Sci Monit 2001; 7: 325–331
- Hale G, Dyer M J, Clark M R, Phillips J M, Marcus R, Riechmann L, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2: 1394–1399
- Dearden C E, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol 2002; 19(Suppl)S27–S32
- Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald A P, Repp R, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004; 103: 2920–2924
- Salisbury J R, Rapson N T, Codd J D, Rogers M V, Nethersell A B. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. J Clin Pathol 1994; 47: 313–317
- Iwamoto N, Nagakura S, Kawaguchi T, Horikawa K, Takatsuki K, Nakakuma H. T-lymphoblastic lymphoma/leukemia cells negative for CD52 and CD59. Int J Hematol 1995; 62: 55–57
- Jaffe E S, Ralfkiaer E. Mature T-cell and NK-cell neoplasms. World Health Organization classification of tumours: Tumours of the haematopoietic and lymphoid tissues, E S Jaffe, N L Harris, H Stein, J W Vardiman. IARC Press, Lyon 2001; 189–235
- Lu D, Lin C N, Chuang S S, Hwang W S, Huang W T. T-cell and NK-cell lymphomas in southern Taiwan: a study of 72 cases in a single institute. Leuk Lymphoma 2004; 45: 923–928
- Ravandi F, O'Brien S, Jones D, Lerner S, Faderl S, Ferrajoli A, et al. T-cell prolymphocytic leukemia: a single-institution experience. Clin Lymph Myeloma 2005; 6: 234–239
- Osuji N, Del Giudice I, Matutes E, Morilla A, Owusu-Ankomah K, Morilla R, et al. CD52 expression in T-cell large granular lymphocyte leukemia—implications for treatment with alemtuzumab. Leuk Lymphoma 2005; 46: 723–727
- Chuang S S, Huang W T, Hsieh P P, Tseng H H, Campo E, Colomer D, et al. Mantle cell lymphoma in Taiwan: a clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2. Pathol Int 2006; 56: 440–448
- Chuang S S, Lin C N, Li C Y. Malignant lymphoma in Southern Taiwan according to the revised European-American classification of lymphoid neoplasms. Cancer 2000; 89: 1586–1592
- Liang R. Diagnosis and management of primary nasal lymphoma of T-cell or NK-cell origin. Clin Lymph Myeloma 2000; 1: 33–37